Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series

Respiratory Medicine
Matthew E FalagasArgyris Michalopoulos

Abstract

Reports of patients with polymyxin-only susceptible gram-negative nosocomial pneumonia treated with inhaled, but without concurrent intravenous, colistin are rare. Patients admitted in a tertiary 450-bed tertiary care centre during the period 05/01/2005-05/31/2007 and receiving colistin through nebulization, but not systemically, were included in this retrospective case series. Five patients (three with ventilator-associated pneumonia and two with nosocomial pneumonia) received colistin through nebulization without concomitant intravenous colistin. The isolated pathogens were Acinetobacter baumannii (three cases), Pseudomonas aeruginosa (one case) and the combination of Klebsiella pneumoniae, A. baumannii and P. aeruginosa (one case). They were susceptible only to colistin (three cases) or to colistin and gentamicin (two cases). Intravenous antimicrobial agents given concurrently were piperacillin/tazobactam, meropenem, ceftriaxone and ciprofloxacin; isolated pathogens were resistant to these agents. Four (80%) out of the five patients were cured, survived and were discharged. One patient died. No colistin-related adverse event was observed. The experience from this case series and other relevant recent reports suggest that tre...Continue Reading

References

Mar 17, 2004·Current Opinion in Infectious Diseases·Michael E Klepser
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrea L H KwaVincent H Tam
Jan 7, 2006·The Journal of Antimicrobial Chemotherapy·F RatjenH Grasemann
Aug 9, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter K Linden, David L Paterson
Aug 26, 2006·The Lancet Infectious Diseases·Jian LiDavid L Paterson
Sep 7, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M E FalagasG Samonis
Dec 22, 2006·The New England Journal of Medicine·UNKNOWN Canadian Critical Care Trials Group
Sep 20, 2007·The Journal of Antimicrobial Chemotherapy·Alexandre Prehn ZavasckiRoger L Nation
Sep 22, 2007·Surgical Infections·Vincent TrottierMark G McKenney
Oct 16, 2007·The Journal of Antimicrobial Chemotherapy·Eleni IoannidouMatthew E Falagas
Jan 9, 2008·Antimicrobial Agents and Chemotherapy·Stephanie J WallaceJohn D Turnidge
Jul 30, 2008·Expert Review of Anti-infective Therapy·Matthew E FalagasIlias I Siempos
Oct 17, 2008·The Journal of Antimicrobial Chemotherapy·Anima PoudyalJian Li

❮ Previous
Next ❯

Citations

Apr 17, 2010·Intensive Care Medicine·Qin LuJean-Jacques Rouby
Oct 3, 2009·Current Opinion in Infectious Diseases·Roger L Nation, Jian Li
Jul 8, 2010·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·S K Todi
Feb 11, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Diana F FlorescuA C Kalil
Feb 16, 2012·Expert Opinion on Drug Delivery·Sabina Antonela Antoniu, Ileana Cojocaru
Jan 9, 2010·Expert Opinion on Emerging Drugs·Marc LeoneClaude Martin
Nov 26, 2009·Expert Opinion on Pharmacotherapy·José MolinaJerónimo Pachón
Nov 27, 2009·International Journal of Antimicrobial Agents·Matthew E FalagasEugenios I Metaxas
Nov 18, 2011·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Hung-Jen TangShyh-Ren Chiang
Dec 16, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D YahavM Paul
Jan 11, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Joana AlvesUNKNOWN SANEME-2 Investigators
Dec 16, 2016·Clinical Microbiology Reviews·Darren WongBrad Spellberg
Oct 4, 2012·Expert Review of Anti-infective Therapy·Silpak BiswasJean-Marc Rolain
Sep 8, 2010·Expert Review of Anti-infective Therapy·Argyris S Michalopoulos, Dimitra C Karatza
Jun 16, 2010·Antimicrobial Agents and Chemotherapy·Sandrine MarchandWilliam Couet
Jul 26, 2017·Drugs·Garyphallia PoulakouGeorge Dimopoulos
Jun 5, 2015·Expert Review of Clinical Pharmacology·Foroud Shahbazi, Simin Dashti-Khavidaki
May 27, 2016·Clinical Microbiology Reviews·Eric WenzlerLarry H Danziger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.